Comparison of circulating and intratumoral regulatory T cells in patients with renal cell carcinoma
- 354 Downloads
The clear evidence that tumor-infiltrating lymphocytes (TIL) exists in the tumor microenvironment raises the question why renal cell carcinoma (RCC) progresses. Numerous studies support the implication of CD4+CD25high regulatory T (Treg) cells in RCC development. We aimed in this study to characterize the phenotype and function of circulating and intratumoral Treg cells of RCC patient in order to evaluate their implication in the inhibition of the local antitumor immune response. Our results demonstrate that the proportion of Treg in TIL was, in average, similar to that found in circulating CD4+ T cells of patients or healthy donors. However, intratumoral Treg exhibit a marked different phenotype when compared with the autologous circulating Treg. A higher CD25 mean level, HLA-DR, Fas, and GITR, and a lower CD45RA expression were observed in intratumoral Treg, suggesting therefore that these cells are effector in the tumor microenvironment. Additionally, intratumoral Treg showed a higher inhibitory function on autologous CD4+CD25− T cells when compared with circulating Treg that may be explained by an overexpression of FoxP3 transcription factor. These findings suggest that intratumoral Treg could be major actors in the impairment of local antitumor immune response for RCC patients.
KeywordsRCC Tumor infiltrate Regulatory T cells Immune response Tumor escape
This work was financially supported by the “PHC Utique” program of the French Ministry of Foreign Affairs and Ministry of higher education and research and the Tunisian Ministry of higher education and scientific research in the CMCU project number 13G0819.
Conflicts of interest
- 19.Polimeno M, Napolitano M, Costantini S, Portella L, Esposito A, Capone F, et al. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int. 2013;112:686–96.CrossRefPubMedGoogle Scholar
- 28.Kim CS, Kim Y, Kwon T, Yoon JH, Kim KH, You D, Hong JH, Ahn H, Jeong IG: Regulatory T cells and TGF-beta1 in clinically localized renal cell carcinoma: comparison with age-matched healthy controls. Urol Oncol 2014. doi: 10.1016/j.urolonc.2014.11.004.